These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 5093249)
1. Current trends in IND-NDA procedures. Brilhart KB Bull Parenter Drug Assoc; 1971; 25(3):132-9. PubMed ID: 5093249 [No Abstract] [Full Text] [Related]
2. Should the FDA impose relative efficacy judgments? Stetler CJ Tex Med; 1972 Nov; 68(11):48-52. PubMed ID: 4634627 [No Abstract] [Full Text] [Related]
3. New classification of drugs. J Fla Med Assoc; 1972 Jan; 59(1):37. PubMed ID: 5058956 [No Abstract] [Full Text] [Related]
4. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories. Jimenez FA Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711 [No Abstract] [Full Text] [Related]
5. Toward more effective drug regulation. Schmidt AM FDA Consum; 1975 Dec-1976 Jan; 9(10):27-9. PubMed ID: 10316532 [No Abstract] [Full Text] [Related]
6. Preclearance of drug products--pharmacy's perspective. Feldmann EG Am Pharm; 1981 Jun; NS21(6):26-32. PubMed ID: 7246421 [No Abstract] [Full Text] [Related]
7. Relationship of USP-NF to NDA and ANDA "Standards". Belson JJ Am J Hosp Pharm; 1982 May; 39(5):869-70. PubMed ID: 7081269 [No Abstract] [Full Text] [Related]
8. Response to the applicability of proposed large volume parenteral regulations to small volume parenteral drug products. Bull Parenter Drug Assoc; 1976; 30(6):265-79. PubMed ID: 1000103 [No Abstract] [Full Text] [Related]
10. Prospects for reform of the IND/NDA processes: Part I. Romansky MA J Clin Psychopharmacol; 1982 Oct; 2(5):358-61. PubMed ID: 6752215 [No Abstract] [Full Text] [Related]
11. View from the Nation's Capital. Investigational new drug (IND) and new drug application (NDA). Romansky MA J Clin Psychopharmacol; 1983 Jun; 3(3):193-4. PubMed ID: 6680405 [No Abstract] [Full Text] [Related]
12. View from the Nation's Capital. New drug application (NDA) and investigational new drug (IND) regulations. Romansky MA J Clin Psychopharmacol; 1983 Dec; 3(6):380-3. PubMed ID: 6680409 [No Abstract] [Full Text] [Related]
13. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products. Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700 [No Abstract] [Full Text] [Related]
14. Antibiotics standards versus standards for other drugs. Wright WW Am J Hosp Pharm; 1982 Jun; 39(6):1046-7. PubMed ID: 7102691 [No Abstract] [Full Text] [Related]
16. Generic vs. brand name drugs--defining and enforcing standards. Lasagna LC Internist; 1979 May; 20(4):11, 13. PubMed ID: 10316827 [No Abstract] [Full Text] [Related]
17. The control of drugs and therapeutic freedom. Dunlop D Proc R Soc Med; 1968 Aug; 61(8):841-6. PubMed ID: 5695368 [No Abstract] [Full Text] [Related]
18. [Theoretical and practical aspects of statistic sampling and related norms of acceptance]. Mattei A; Pietra E Boll Chim Farm; 1968 May; 107(5):287-95. PubMed ID: 5721540 [No Abstract] [Full Text] [Related]
19. Regulating drugs for effectiveness and safety: a public health perspective. Zito JM; Socolar SJ; Eilers R; Crystal S; Lexchin J Med Care; 2007 Sep; 45(9):911. PubMed ID: 17712264 [No Abstract] [Full Text] [Related]
20. Benefits and liabilities of generic prescribing. Lee AM W V Med J; 1972 Jun; 68(6):161-6. PubMed ID: 4504384 [No Abstract] [Full Text] [Related] [Next] [New Search]